Physician profile
Olan Halim
NPI 1295751584
$2,524.01
in general payments reported to CMS, 2019-2025
27 companies · $1,107 in 2025
The $1,107 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $19.72 · 2021: $19.60 · 2022: $28.03 · 2023: $367 · 2024: $735 · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,208.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $567.13 | 2022-2025 | Vraylar, Qulipta |
| Lilly USA, LLC | $338.80 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.77 | 2019-2025 | Jardiance |
| Inspire Medical Systems, INC. | $192.07 | 2025 | Inspire |
| Intuitive Surgical, INC. | $128.99 | 2025 | |
| Exact Sciences Corporation | $122.19 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $92.77 | 2023-2025 | Airsupra, Evusheld, Farxiga |
| Glaxosmithkline, LLC. | $79.81 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Medtronic, INC. | $77.77 | 2025 | Protege Rx |
| Bayer Healthcare Pharmaceuticals INC. | $65.78 | 2023 | |
| Janssen Pharmaceuticals, INC | $65.69 | 2023-2025 | Xarelto, Spravato |
| Novo Nordisk INC | $61.94 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $47.77 | 2025 | Korlym |
| Eisai INC. | $44.76 | 2024 | |
| Astellas Pharma US INC | $44.75 | 2023-2025 | Veozah, Myrbetriq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $44.57 | 2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $42.86 | 2023-2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $33.60 | 2024 | Voquezna |
| Sumitomo Pharma America, INC. | $20.82 | 2024 | Gemtesa |
| Axonics, INC. | $20.54 | 2023 | Axonics |
| Insmed, INC. | $19.87 | 2025 | Arikayce |
| Azurity Pharmaceuticals, INC. | $19.67 | 2025 | Edarbi |
| Antares Pharma, INC. | $19.24 | 2025 | Xyosted |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.08 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.51 | 2024 | Xifaxan |
| Noven Therapeutics, LLC | $15.54 | 2025 | Xelstrym |
| Amgen INC. | $13.72 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olan Halim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.